| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
UCB SA (BR: UCB)
UCB Technical Analysis
5
| As on 12th Nov 2025 UCB STOCK Price closed @ 229.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 167.41 & Strong Buy for SHORT-TERM with Stoploss of 145.29 we also expect STOCK to react on Following IMPORTANT LEVELS. |
UCBSTOCK Price
| Open | 230.00 | Change | Price | % |
| High | 232.50 | 1 Day | 2.60 | 1.15 |
| Low | 228.20 | 1 Week | 9.50 | 4.32 |
| Close | 229.50 | 1 Month | -16.20 | -6.59 |
| Volume | 361603 | 1 Year | 99.45 | 76.47 |
| 52 Week High 260.20 | 52 Week Low 129.35 | ||||
BR Belgium Most Active Stocks
| OPTI | 0.01 | % |
| SCHD | 25.71 | 2.72% |
| ABI | 56.14 | 0.54% |
| BOTHE | 0.29 | 70.59% |
| ACPH | 0.89 | 0.00% |
| UMI | 17.19 | 2.87% |
| KBC | 109.80 | 0.97% |
| PROX | 6.84 | -0.73% |
| UCB | 229.50 | 1.15% |
| WDP | 22.36 | 0.27% |
BR Belgium Top Gainers Stocks
BR Belgium Top Losers Stocks
| UCB Daily Charts |
UCB Intraday Charts |
Whats New @ Bazaartrend |
UCB Free Analysis |
|
|
UCB Important Levels Intraday
| RESISTANCE | 237.79 |
| RESISTANCE | 235.13 |
| RESISTANCE | 233.49 |
| RESISTANCE | 231.84 |
| SUPPORT | 227.16 |
| SUPPORT | 225.51 |
| SUPPORT | 223.87 |
| SUPPORT | 221.21 |
UCB Forecast November 2025
| 4th UP Forecast | 278.06 |
| 3rd UP Forecast | 262.49 |
| 2nd UP Forecast | 252.86 |
| 1st UP Forecast | 243.23 |
| 1st DOWN Forecast | 215.77 |
| 2nd DOWN Forecast | 206.14 |
| 3rd DOWN Forecast | 196.51 |
| 4th DOWN Forecast | 180.94 |
UCB Weekly Forecast
| 4th UP Forecast | 239.42 |
| 3rd UP Forecast | 236.24 |
| 2nd UP Forecast | 234.27 |
| 1st UP Forecast | 232.31 |
| 1st DOWN Forecast | 226.69 |
| 2nd DOWN Forecast | 224.73 |
| 3rd DOWN Forecast | 222.76 |
| 4th DOWN Forecast | 219.58 |
UCB Forecast2025
| 4th UP Forecast | 488.1 |
| 3rd UP Forecast | 405.17 |
| 2nd UP Forecast | 353.9 |
| 1st UP Forecast | 302.64 |
| 1st DOWN Forecast | 156.36 |
| 2nd DOWN Forecast | 105.1 |
| 3rd DOWN Forecast | 53.83 |
| 4th DOWN Forecast | -29.1 |
UCB SA ( BR Belgium Symbol : UCB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
UCB Business Profile
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium. Address: AllEe de la Recherche, 60, Brussels, Belgium, 1070
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service